TY - JOUR
T1 - Acceptability and attitude towards a mobile-based home exercise program among stroke survivors and caregivers
T2 - A cross-sectional study
AU - Mahmood, Amreen
AU - Blaizy, Vevita
AU - Verma, Aparajita
AU - Sequeira, Joel Stephen
AU - Saha, Dola
AU - Ramachandran, Selvam
AU - Manikandan, N.
AU - Unnikrishnan, Bhaskaran
AU - Solomon, John M.
N1 - Funding Information:
The funder of the study was involved in study design, data collection, data analysis, and data interpretation. Employees of the funder were authors on this paper, and were therefore involved in writing of the report. Editorial support in styling, formatting, and submitting this report was provided by a medical writer funded by the sponsor. The corresponding author and senior author had full access to all the data in the study, vouch for the accuracy and completeness of data reported, and had final responsibility for the decision to submit for publication.
Funding Information:
SK has received research grants and consulting fees from Bayer, research grants from Daiichi Sankyo, and speaker fees from Bristol-Myers Squibb and AstraZeneca. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the advisory board, steering committee, or executive committee for Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, Vifor Pharma, Novartis, Amgen, Merck, Janssen Research & Development, Menarini, Boehringer Ingelheim, Novo Nordisk, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global, Radcliffe Group, and Corpus; and serves as cofounder and non-executive director of eKo.ai. DJK has received research grant support from LG Life Sciences, Chong Kun Dang, and AstraZeneca; has been a consultant for AstraZeneca, Novo Nordisk, and Sanofi; and has received speaker fees from Novo Nordisk, Takeda, Handok, CJ Healthcare, Chong Kun Dang, MSD, Hanmi, and AstraZeneca. MAC has received research grants and personal fees from Amgen, personal fees from AstraZeneca, Chiesi, Boehringer Ingelheim, Novo Nordisk, and Merck; and research grants from Bristol Myers Squibb, CSL Behring, and Novartis. AN has received honoraria for lectures and advisory board meetings from AstraZeneca, Novo Nordisk, MSD, Boehringer Ingelheim, and Lilly. MEJ has received research grants from AstraZeneca, Amgen, Boehringer Ingelheim, and Sanofi Aventis; is a shareholder of Novo Nordisk; and has received speaker fees from Novo Nordisk. KIB has received research grants and non-financial support (for keeping and maintaining the database and statistical analyses) from AstraZeneca related to the present study; and research grants from Boehringer Ingelheim, MSD, Sanofi, Novo Nordisk, and Eli Lilly. RWH has received research grants to his institution from AstraZeneca, including support for the present study. NT has received consulting fees from Boehringer Ingelheim, Eli Lilly, Otsuka, and AstraZeneca; research grants from AstraZeneca, including support for the present study; research grants from Janssen and Tricida; and consulting fees and stock options from Tricida, PulseData, and Mesentech. JES has received honoraria for advisory board participation and lectures from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mylan Pharmaceuticals, and Novo Nordisk. JI has consulted for AstraZeneca Australia. AK has received consulting fees from AstraZeneca, Novo Nordisk, and Boehringer Ingelheim. S-YG has received research grants to her institution from AstraZeneca, Medtronic, and Sanofi; and honoraria for advisory board participation for Amgen, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Medtronic, and Sanofi. C-EC has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, and Sanofi. MT is an employee of Statisticon, for which AstraZeneca is a client. HC, EW, FS, and PF are AstraZeneca employees and hold stock options in the company. JB is an AstraZeneca employee. MK has received research grants from AstraZeneca and Boehringer Ingelheim; and has served as a consultant for Amarin, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Glytec, Novo Nordisk, Janssen, Merck (Diabetes), Novartis, Sanofi, and Vifor Pharma.
Publisher Copyright:
© 2019 Amreen Mahmood et al.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background. Stroke is a leading cause of disability and requires continued care after hospital discharge. Mobile-based interventions are suitable to reduce the cost of stroke rehabilitation and facilitate self-management among stroke survivors. However, before attempting to use mobile-based home exercise program, it is crucial to recognize the readiness of stroke survivors and their caregivers to opt for such interventions. Objective. To assess the acceptability and attitude towards a mobile-based home exercise program among stroke survivors and their primary caregivers. Methods. A cross-sectional study was conducted among 102 participants to understand their attitude and acceptability towards mobile-based home exercise program. A validated 10-item questionnaire was adapted for the study. The questions which assessed the attitude were rated on a three-point Likert scale, with three denoting agree and one denoting disagree. The acceptability was assessed by their willingness to opt for a mobile-based home program services. A Chi-square analysis and cross-tabulation were performed to test differences between caregivers and patients. A logistic regression was performed to determine the effects of age, gender, and mobile phone on acceptability. Results. Ninety-two percent of caregivers and 90% of patients showed willingness to opt for mobile-based intervention. Majority of the participants showed a positive attitude towards this mode of treatment. There was no difference in the attitude noted among caregivers and patients (p>0.05) towards mobile-based intervention. Conclusion. The stroke survivors and caregivers welcomed the concept of mobile-based home exercise program even in a low-resource settings, but further studies to understand treatment and cost-effectiveness of this technology among the stroke survivors would lead to better implementation.
AB - Background. Stroke is a leading cause of disability and requires continued care after hospital discharge. Mobile-based interventions are suitable to reduce the cost of stroke rehabilitation and facilitate self-management among stroke survivors. However, before attempting to use mobile-based home exercise program, it is crucial to recognize the readiness of stroke survivors and their caregivers to opt for such interventions. Objective. To assess the acceptability and attitude towards a mobile-based home exercise program among stroke survivors and their primary caregivers. Methods. A cross-sectional study was conducted among 102 participants to understand their attitude and acceptability towards mobile-based home exercise program. A validated 10-item questionnaire was adapted for the study. The questions which assessed the attitude were rated on a three-point Likert scale, with three denoting agree and one denoting disagree. The acceptability was assessed by their willingness to opt for a mobile-based home program services. A Chi-square analysis and cross-tabulation were performed to test differences between caregivers and patients. A logistic regression was performed to determine the effects of age, gender, and mobile phone on acceptability. Results. Ninety-two percent of caregivers and 90% of patients showed willingness to opt for mobile-based intervention. Majority of the participants showed a positive attitude towards this mode of treatment. There was no difference in the attitude noted among caregivers and patients (p>0.05) towards mobile-based intervention. Conclusion. The stroke survivors and caregivers welcomed the concept of mobile-based home exercise program even in a low-resource settings, but further studies to understand treatment and cost-effectiveness of this technology among the stroke survivors would lead to better implementation.
UR - http://www.scopus.com/inward/record.url?scp=85066069630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066069630&partnerID=8YFLogxK
U2 - 10.1155/2019/5903106
DO - 10.1155/2019/5903106
M3 - Article
AN - SCOPUS:85066069630
SN - 1687-6415
VL - 2019
JO - International Journal of Telemedicine and Applications
JF - International Journal of Telemedicine and Applications
M1 - 5903106
ER -